TVR110, an experimental RNA therapy designed to treat Charcot-Marie-Tooth disease type 1A (CMT1A), showed promising signs of efficacy and an encouraging safety profile in tests done in animals, a study reported. The preclinical work was funded by Armatus Bio, the company developing TVR110. Scientists at Armatus conducted the…
Discussion
Last in a series. Read parts one, two, and three. While physical strength may seem narrowly and clearly defined, it intersects with many aspects of our lives. It’s a topic I considered with newfound fascination after reading “On Muscle: The Stuff That Moves Us and Why It…
Becoming educated and informed about Charcot-Marie-Tooth disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your CMT journey.
There is no cure for CMT yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
